Climacteric

Climacteric
Audio Summaries

Climacteric : the journal of the International Menopause Society

Every issue of Climacteric moves the field forward, but reading every paper cover-to-cover isn't realistic. OSLR turns each article into a 3-minute audio summary so you can stay current while you commute, round, or work out.

177 audio summariesNLM Catalog

Specialties

Climacteric covers research in these specialties.

Recent summaries

The latest articles summarized from Climacteric.

GESS-AEEM consensus on testosterone therapy in women: a clinical implementation framework.

Nov 19, 2026

This Spanish multidisciplinary consensus, built from a literature review (2000–April 2026) and a two-round modified Delphi process, asks how systemic testosterone therapy in women can be implemented safely and consistently in clinical practice in Spain and comparable European settings. The panel concludes that physiological-dose transdermal testosterone may be considered for postmenopausal women with hypoactive sexual desire disorder after a comprehensive biopsychosocial assessment, while serum testosterone should be used for safe prescribing and monitoring rather than diagnosis. Non-transdermal formulations, supraphysiological doses, and non-sexual indications are not supported, and the authors explicitly state that the document does not create a new indication or replace existing guidelines.

Dry eye disease in the menopausal transition: toward recognition as a hormonal manifestation.

Nov 17, 2026

This opinion piece argues that dry eye disease should be recognized as a hormonally mediated manifestation of the menopausal transition, given that it affects an estimated 64-80% of peri- and postmenopausal women and that postmenopausal women show worse objective ocular surface signs than premenopausal women even with similar symptoms. The authors ask whether dry eye can be framed as "menopausal dry eye," driven by androgen deficiency and altered estrogen signaling. They recommend routine screening with the Ocular Surface Disease Index-6, counseling on the ocular effects of hormone therapy, and timely eye care referral for persistent or moderate-to-severe symptoms.

Intracrinology and tissue-selective effects of tibolone: mechanisms and implications.

Nov 16, 2026

This critical narrative review asks whether intracrinology, the local conversion of circulating steroid precursors into active or inactive hormones within target tissues, can explain tibolone's tissue-selective effects. The authors find that tibolone acts as a prodrug yielding estrogenic, progestogenic, and androgenic metabolites whose local availability may differ by tissue due to enzyme expression, sulfation/desulfation, and transport. They conclude that intracrinology is a biologically plausible framework, but clinical evidence is largely compatible with rather than confirmatory of this mechanism, with benefit-risk balance varying by tissue and patient context.

The breast at perimenopause.

Nov 13, 2026

This narrative review examines how the hormonal fluctuations and metabolic changes of perimenopause affect breast health, including benign breast disease, breast cancer risk, and treatment decisions. The authors ask how breast cancer risk factors, subtypes, incidence, and prognosis differ across the menopausal stages and between populations, and how these differences should shape screening, prevention, and endocrine therapy choices (such as tamoxifen versus aromatase inhibitors) for women in perimenopause. They also consider the influence of hormonal contraception and menopausal hormone therapy on these outcomes.

Mindfulness-based stress reduction for sleep quality and emotional state in menopause-related insomnia symptoms.

Nov 11, 2026

This randomized controlled trial asked whether adding 12 weeks of mindfulness-based stress reduction (MBSR) to routine health care improves sleep, anxiety, depression, coping, and quality of life in women with menopause-related insomnia symptoms. Eighty-two patients were randomized to MBSR plus routine care or routine care alone, and the MBSR group showed significantly greater improvements in anxiety, depression, Pittsburgh Sleep Quality Index scores, coping styles, and several quality-of-life domains (p < 0.01). The authors also reported high adherence in both arms, adverse events below 5% with no serious events, and concluded that MBSR is a safe and effective add-on intervention.

A new concept for 'starting menopause hormone therapy' using an oral GnRH antagonist with an estrogen and a progestin (or an estrogen and a selective estrogen receptor modulator): why must we wait to treat women in perimenopause?

Nov 11, 2026

This proof-of-concept paper proposes a "starting menopause hormone therapy" (sMHT) approach that uses an oral GnRH antagonist combined with an estrogen and a progestin (or a SERM) to treat vasomotor symptoms and abnormal uterine bleeding as soon as they appear in perimenopause, rather than waiting for 12 months of amenorrhea. The authors ask whether the availability of oral GnRH antagonists makes it possible to start hormone treatment earlier in symptomatic perimenopausal women, avoiding the safety and adherence drawbacks of combined oral contraceptives or sequential estro-progestin regimens. They suggest that sMHT could later transition to conventional MHT once ovarian function has definitively ceased.

Challenges in perimenopause research and the application of existing criteria for staging reproductive aging in low and middle-income countries: a scoping review.

Nov 9, 2026

This narrative scoping review asks how perimenopause research in low and middle-income countries (LMICs) is conducted and whether reproductive-stage classification is consistent with recognized frameworks such as STRAW +10. Of 90 included studies (2005 to June 2026), most were cross-sectional, only 7.8% were longitudinal, and classification varied widely: STRAW +10 was used in 20.0%, STRAW in 21.0%, WHO criteria in 10.0%, and 48.9% relied on menstrual history without citing a staging framework. The authors conclude that wider adoption of standardized frameworks like STRAW +10, along with stronger methodological rigor, is needed to make LMIC perimenopause research more comparable and applicable.

Perimenopause as a critical neuro-musculoskeletal window for healthy aging: integrating brain, bone and muscle health.

Nov 3, 2026

This narrative review asks whether perimenopause should be recognized as a critical window affecting bone, muscle, and brain health together, rather than being viewed only as a reproductive transition. The authors synthesize evidence showing robust bone loss during this period, more heterogeneous findings for muscle and objective cognitive change, and biological plausibility for interactions among these systems via endocrine, inflammatory, and mitochondrial pathways. They propose a "bone-brain-muscle axis" as a conceptual clinical framework to support earlier, individualized risk identification, while explicitly noting that direct evidence for this integrated model during perimenopause remains limited.

Perimenopause and cardiometabolic risk: emerging evidence, therapeutic opportunities and unanswered questions.

Nov 2, 2026

This review examines whether perimenopause, the transition period around the final menstrual period, represents a critical window where cardiometabolic risk and menopause symptoms intersect. The authors synthesize evidence that vasomotor symptoms and sleep disturbance are linked to adverse lipid, insulin, body composition, and vascular profiles, with autonomic, inflammatory, and neuroendocrine pathways as possible shared mechanisms. They conclude that the relationship appears bidirectional, but the absence of perimenopausal interventional studies leaves causality and whether targeting cardiometabolic health can improve both cardiovascular outcomes and symptoms unresolved.

Managing the transition without hormones.

Oct 22, 2026

The authors aim to address the need for effective non-hormonal management strategies for women experiencing perimenopause, particularly given that many prefer alternatives to menopause hormone therapy (MHT). They review evidence-based approaches for various symptoms associated with this transition and propose a structured, symptom-oriented clinical framework to guide personalized treatment decisions. The article emphasizes the importance of shared decision-making and ongoing assessment to optimize care for women during this complex phase.

Listen to Climacteric

14-day free trial. Every new article, summarized in ~3 minutes.